IBRX vs. RVMD, ROIV, BBIO, BPMC, ELAN, LEGN, TGTX, LNTH, VRNA, and TLX
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Revolution Medicines (RVMD), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Lantheus (LNTH), Verona Pharma (VRNA), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry.
ImmunityBio vs.
ImmunityBio (NASDAQ:IBRX) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.
Revolution Medicines has a net margin of 0.00% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Revolution Medicines' return on equity.
8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 76.8% of ImmunityBio shares are held by company insiders. Comparatively, 8.2% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
ImmunityBio has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
Revolution Medicines has lower revenue, but higher earnings than ImmunityBio. Revolution Medicines is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
ImmunityBio presently has a consensus target price of $12.25, indicating a potential upside of 322.41%. Revolution Medicines has a consensus target price of $67.08, indicating a potential upside of 65.76%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImmunityBio is more favorable than Revolution Medicines.
Revolution Medicines received 78 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 78.03% of users gave Revolution Medicines an outperform vote while only 54.35% of users gave ImmunityBio an outperform vote.
In the previous week, Revolution Medicines had 12 more articles in the media than ImmunityBio. MarketBeat recorded 27 mentions for Revolution Medicines and 15 mentions for ImmunityBio. Revolution Medicines' average media sentiment score of 1.06 beat ImmunityBio's score of 0.52 indicating that Revolution Medicines is being referred to more favorably in the news media.
Summary
Revolution Medicines beats ImmunityBio on 11 of the 19 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
This page (NASDAQ:IBRX) was last updated on 5/21/2025 by MarketBeat.com Staff
